The twists and turns in U.S. President Donald Trump's tariff policies have not only roiled global financial markets but also ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...

Greg Abbott wants more than 50 Democratic lawmakers who fled the state hauled back and arrested. Now, one legislator has been ...

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...

Twenty-two projects, totaling $500 million, to develop vaccines using mRNA technology will be halted, the health secretary ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

US stocks end lower after data show higher prices and lower employment. Investors also weigh earnings and Trump tariff threats.

President Trump’s latest tariff threat has targeted a sector that’s already hobbled.

President Trump threatened 250% tariffs on pharma; Pfizer CEO contacted Trump about most favored nation pricing; Ex-X CEO joins eMed.

The Trump administration on Tuesday announced it would terminate 22 federal contracts for mRNA-based vaccines despite safety ...